KR20030055265A - CD11b 발현 세포로의 분자 전달용 벡터 - Google Patents
CD11b 발현 세포로의 분자 전달용 벡터 Download PDFInfo
- Publication number
- KR20030055265A KR20030055265A KR10-2003-7003818A KR20037003818A KR20030055265A KR 20030055265 A KR20030055265 A KR 20030055265A KR 20037003818 A KR20037003818 A KR 20037003818A KR 20030055265 A KR20030055265 A KR 20030055265A
- Authority
- KR
- South Korea
- Prior art keywords
- adenylcyclase
- cells
- cyaa
- cd11b
- molecule
- Prior art date
Links
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 title claims abstract description 169
- 102100022338 Integrin alpha-M Human genes 0.000 title claims abstract description 169
- 239000013598 vector Substances 0.000 title claims abstract description 65
- 108060000200 adenylate cyclase Proteins 0.000 claims abstract description 147
- 102000030621 adenylate cyclase Human genes 0.000 claims abstract description 146
- 239000003053 toxin Substances 0.000 claims abstract description 79
- 231100000765 toxin Toxicity 0.000 claims abstract description 79
- 239000000203 mixture Substances 0.000 claims abstract description 56
- 241000588807 Bordetella Species 0.000 claims abstract description 51
- 238000001727 in vivo Methods 0.000 claims abstract description 36
- 230000002163 immunogen Effects 0.000 claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- 230000028993 immune response Effects 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 247
- 239000000427 antigen Substances 0.000 claims description 90
- 108091007433 antigens Proteins 0.000 claims description 88
- 102000036639 antigens Human genes 0.000 claims description 88
- 230000027455 binding Effects 0.000 claims description 75
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 57
- 230000003197 catalytic effect Effects 0.000 claims description 49
- 210000004443 dendritic cell Anatomy 0.000 claims description 47
- 241000588832 Bordetella pertussis Species 0.000 claims description 32
- 210000000172 cytosol Anatomy 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 29
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 27
- 210000000440 neutrophil Anatomy 0.000 claims description 27
- 230000008685 targeting Effects 0.000 claims description 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 25
- 230000003834 intracellular effect Effects 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 16
- 239000002671 adjuvant Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 238000001990 intravenous administration Methods 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 231100000252 nontoxic Toxicity 0.000 claims description 6
- 230000003000 nontoxic effect Effects 0.000 claims description 6
- 108010015899 Glycopeptides Proteins 0.000 claims description 5
- 102000002068 Glycopeptides Human genes 0.000 claims description 5
- 108010028921 Lipopeptides Proteins 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 229920001542 oligosaccharide Polymers 0.000 claims description 5
- 150000002482 oligosaccharides Chemical class 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 241000991587 Enterovirus C Species 0.000 claims description 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 4
- 230000003071 parasitic effect Effects 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 101710095468 Cyclase Proteins 0.000 claims description 3
- 201000009906 Meningitis Diseases 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 108700012359 toxins Proteins 0.000 description 72
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 61
- 102100025390 Integrin beta-2 Human genes 0.000 description 61
- 102100022297 Integrin alpha-X Human genes 0.000 description 58
- 210000001744 T-lymphocyte Anatomy 0.000 description 45
- 108090000623 proteins and genes Proteins 0.000 description 37
- 238000000338 in vitro Methods 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 32
- 210000000612 antigen-presenting cell Anatomy 0.000 description 27
- 230000004044 response Effects 0.000 description 26
- 210000003719 b-lymphocyte Anatomy 0.000 description 25
- 210000004988 splenocyte Anatomy 0.000 description 25
- 101000609767 Dromaius novaehollandiae Ovalbumin Proteins 0.000 description 22
- 230000000638 stimulation Effects 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 20
- 102000006495 integrins Human genes 0.000 description 19
- 108010044426 integrins Proteins 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 18
- 230000003053 immunization Effects 0.000 description 18
- 102100020873 Interleukin-2 Human genes 0.000 description 17
- 108010002350 Interleukin-2 Proteins 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 238000002649 immunization Methods 0.000 description 17
- 230000003993 interaction Effects 0.000 description 17
- 210000002540 macrophage Anatomy 0.000 description 17
- 102000005962 receptors Human genes 0.000 description 17
- 108020003175 receptors Proteins 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 16
- 230000001419 dependent effect Effects 0.000 description 15
- 238000000099 in vitro assay Methods 0.000 description 14
- 238000000684 flow cytometry Methods 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 229960002685 biotin Drugs 0.000 description 12
- 239000011616 biotin Substances 0.000 description 12
- 101150101102 cyaA gene Proteins 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 230000030833 cell death Effects 0.000 description 11
- 210000000265 leukocyte Anatomy 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 230000030741 antigen processing and presentation Effects 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- 101150096136 cyaC gene Proteins 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000037361 pathway Effects 0.000 description 10
- 108010004729 Phycoerythrin Proteins 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 210000004408 hybridoma Anatomy 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 230000005945 translocation Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 101150013553 CD40 gene Proteins 0.000 description 6
- 229920002271 DEAE-Sepharose Polymers 0.000 description 6
- 102000043129 MHC class I family Human genes 0.000 description 6
- 108091054437 MHC class I family Proteins 0.000 description 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 230000009870 specific binding Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- WTKQMHWYSBWUBE-UHFFFAOYSA-N (3-nitropyridin-2-yl) thiohypochlorite Chemical compound [O-][N+](=O)C1=CC=CN=C1SCl WTKQMHWYSBWUBE-UHFFFAOYSA-N 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 101100276209 Rhizobium meliloti (strain 1021) cya1 gene Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000001516 cell proliferation assay Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 101150084863 cya gene Proteins 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 210000003714 granulocyte Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000000584 Calmodulin Human genes 0.000 description 4
- 108010041952 Calmodulin Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 4
- 101100462972 Mus musculus Pcdh8 gene Proteins 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 230000001593 cAMP accumulation Effects 0.000 description 4
- 230000006037 cell lysis Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 231100000699 Bacterial toxin Toxicity 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010081690 Pertussis Toxin Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 239000000688 bacterial toxin Substances 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000012412 chemical coupling Methods 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000010228 ex vivo assay Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000013227 macrophage apoptotic process Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QLPHBNRMJLFRGO-YDHSSHFGSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexyl]pentanamide Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCCNC(=O)CCSSC1=CC=CC=N1 QLPHBNRMJLFRGO-YDHSSHFGSA-N 0.000 description 2
- 108010083528 Adenylate Cyclase Toxin Proteins 0.000 description 2
- 241000588779 Bordetella bronchiseptica Species 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- 102000005548 Hexokinase Human genes 0.000 description 2
- 108700040460 Hexokinases Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004073 interleukin-2 production Effects 0.000 description 2
- 231100000568 intoxicate Toxicity 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000000207 lymphocyte subset Anatomy 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000026792 palmitoylation Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 238000003133 propidium iodide exclusion Methods 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- YZZUQHDYJXWFNG-VVEMGJRMSA-N (1S,2R,3S,3'S,5R,6S,7R,8S,9R,12R)-2,8-dihydroxy-3'-[(1S)-1-hydroxyethyl]-7-methyl-12-prop-1-en-2-ylspiro[4,10-dioxatetracyclo[7.2.1.02,7.03,5]dodecane-6,5'-oxolane]-2',11-dione Chemical compound C[C@@H]([C@@H]1C[C@]2([C@H]3[C@H](O3)[C@@]4([C@]2([C@@H]([C@H]5[C@H]([C@@H]4C(=O)O5)C(=C)C)O)C)O)OC1=O)O YZZUQHDYJXWFNG-VVEMGJRMSA-N 0.000 description 1
- UVGHPGOONBRLCX-NJSLBKSFSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-NJSLBKSFSA-N 0.000 description 1
- SOGTULYCPNFAGT-YFKPBYRVSA-N (2r)-2-amino-3-[(3-nitropyridin-2-yl)disulfanyl]propanoic acid Chemical class OC(=O)[C@@H](N)CSSC1=NC=CC=C1[N+]([O-])=O SOGTULYCPNFAGT-YFKPBYRVSA-N 0.000 description 1
- UYYRDZGZGNYVBA-VPXCCNNISA-N (2s,3r,4s,5r,6r)-2-[2-chloro-4-[3-(3-chloro-4-hydroxyphenyl)-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(Cl)C(O)=CC=2)C=C1Cl UYYRDZGZGNYVBA-VPXCCNNISA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- XQDQRCRASHAZBA-UHFFFAOYSA-N 2,4-dinitro-1-thiocyanatobenzene Chemical compound [O-][N+](=O)C1=CC=C(SC#N)C([N+]([O-])=O)=C1 XQDQRCRASHAZBA-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- -1 6- (biotinamido) hexyl Chemical group 0.000 description 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100022187 Caenorhabditis elegans mab-10 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- YXQDRIRSAHTJKM-IMJSIDKUSA-N Cys-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YXQDRIRSAHTJKM-IMJSIDKUSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001018064 Homo sapiens Lysosomal-trafficking regulator Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102100033472 Lysosomal-trafficking regulator Human genes 0.000 description 1
- 241001293418 Mannheimia haemolytica Species 0.000 description 1
- 244000038561 Modiola caroliniana Species 0.000 description 1
- 235000010703 Modiola caroliniana Nutrition 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100019396 Mus musculus Itgax gene Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108010077960 Neurocalcin Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- YZZUQHDYJXWFNG-UHFFFAOYSA-N Pretoxin Natural products CC(O)C1CC2(OC1=O)C1OC1C1(O)C3C(C(OC3=O)C(O)C21C)C(C)=C YZZUQHDYJXWFNG-UHFFFAOYSA-N 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 101150038209 cycC gene Proteins 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 101150079947 hlyB gene Proteins 0.000 description 1
- 101150104052 hlyD gene Proteins 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- FEJKNRQBPLHDAB-UHFFFAOYSA-N hydroxy-(3-nitropyridin-2-yl)-oxo-sulfanylidene-$l^{6}-sulfane Chemical group [O-][N+](=O)C1=CC=CN=C1S(S)(=O)=O FEJKNRQBPLHDAB-UHFFFAOYSA-N 0.000 description 1
- 230000006450 immune cell response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- JYOAXOMPIXKMKK-UHFFFAOYSA-N leucyl-glutamine Chemical compound CC(C)CC(N)C(=O)NC(C(O)=O)CCC(N)=O JYOAXOMPIXKMKK-UHFFFAOYSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000030505 negative regulation of chemotaxis Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000031972 neutrophil apoptotic process Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 108010083127 phage repressor proteins Proteins 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 231100000051 skin sensitiser Toxicity 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000003774 sulfhydryl reagent Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 230000024033 toxin binding Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 108010055094 transporter associated with antigen processing (TAP) Proteins 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y406/00—Phosphorus-oxygen lyases (4.6)
- C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
- C12Y406/01001—Aodenylate cyclase (4.6.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
CyaAE5-CyaOVA에 커플링된 NPys CTL 펩티드 | |
에피토프 명칭 | 펩티드의 아미노산 서열 |
CEA 571Gp100멜란A티로시나제 | Cys(NPys)-GGYLSGANLNLCys(NPys)-GGITDQVPFSVCys(NPys)-GGEAAGIGILTVCys(NPys)-GGYMDGTMSQV |
Claims (56)
- 대상 분자를 CD11b 발현 세포에 특이적으로 표적화하는 단백질성 벡터의 제조에 있어서 사용되는 보르데텔라(Bordetella) 종의 아데닐시클라제의 용도.
- 대상 분자를 CD11b 발현 세포에 표적화하기 위한 조성물 제조에 사용되는 대상 분자를 삽입하여 변형시킨 보르데텔라 아데닐시클라제의 용도.
- 제2항에 있어서, 보르데텔라 종의 아데닐시클라제는 보르데텔라 아데닐시클라제 독소의 단편이고, 이 단편은 CD11b 수용체에 결합할 수 있는 것인 용도.
- 제3항에 있어서, CD11b 수용체에 결합할 수 있는 보르데텔라 아데닐시클라제 독소의 단편은 N-말단 촉매 도메인의 전부 또는 일부가 결여된 보르데텔라 아데닐시클라제 독소인 것인 용도.
- 제4항에 있어서, CD11b 수용체에 결합할 수 있는 보르데텔라 아데닐시클라제 독소의 단편은 잔기 1-373의 전부 또는 일부가 결여된 보르데텔라 퍼투시스(Bordetella pertussis) 아데닐시클라제 독소인 것인 용도.
- 제1항 내지 제5항 중 어느 하나의 항에 있어서, 대상 분자의 표적화가 생체내에서 유효한 것인 용도.
- 제1항 내지 제6항 중 어느 하나의 항에 있어서, 대상 분자가 특이적으로 표적화되어 CD11b 발현 세포의 시토졸에서 전위되는 것인 용도.
- 제1항 내지 제7항 중 어느 하나의 항에 있어서, 상기 CD11b 발현 세포는 수지상 세포, 더욱 바람직하게는 골수 수지상 세포인 것인 용도.
- 제1항 내지 제8항 중 어느 하나의 항에 있어서, 상기 CD11b 발현 세포는 호중구인 것인 용도.
- 제1항 내지 제9항 중 어느 하나의 항에 있어서, 아데닐시클라제는 유전자 변형된 보르데텔라 종의 아데닐시클라제인 것인 용도.
- 제1항 내지 제10항 중 어느 하나의 항에 있어서, 아데닐시클라제는 비독성 형태인 것인 용도.
- 제1항 내지 제11항 중 어느 하나의 항에 있어서, 아데닐시클라제는 보르데텔라 퍼투시스에서 유래한 것인 용도.
- 제1항 내지 제12항 중 어느 하나의 항에 있어서, 대상 분자는 펩티드, 글리코펩티드, 리포펩티드, 다당류, 올리고당류, 핵산, 지질 및 화학약품으로 구성된 군에서 선택되는 것인 용도.
- 제13항에 있어서, 대상 분자는 항원인 것인 용도.
- 제13항에 있어서, 대상 분자는 에피토프를 포함하는 것인 용도.
- 제15항에 있어서, 대상 분자는 N-말단 촉매 도메인의 전부 또는 일부가 결여된 유전자 변형 보르데텔라 아데닐시클라제, 더욱 바람직하게는 잔기 1-373이 결여된 보르데텔라 퍼투시스 아데닐시클라제의 N-말단 단부에 융합된 이종성 펩티드인 것인 용도.
- 제14항에 있어서, 상기 항원은 세포내 박테리아 세포 항원, 종양 세포 항원, 바이러스 항원, 진균류 항원 또는 기생충 세포 항원으로 구성된 군에서 선택되는 것인 용도.
- 제17항에 있어서, 상기 항원은 폴리오바이러스 항원, HIV 바이러스 항원, 인플루엔자 바이러스 항원, 맥락수막염 바이러스 에피토프, 종양 항원으로 구성된 군에서 선택되는 것인 용도.
- 제1항 내지 제13항 중 어느 하나의 항에 있어서, 대상 분자는 아데닐시클라제 독소에 화학적으로 또는 유전자적으로 커플링된 약물인 것인 용도.
- 제19항에 있어서, 상기 약물은 아데닐시클라제의 촉매 도메인에 위치한 유전자 삽입된 시스테인 잔기에 이황화 결합을 통해 화학적으로 커플링되어 있는 것인 용도.
- 제19항 또는 제20항에 있어서, 약물은 항염증성 약물인 것인 용도.
- 인간 또는 동물 숙주에게 투여하기 위해 제형화된 면역원성 조성물로서, 촉매 도메인에 삽입된 항원을 포함하는 보르데텔라 아데닐시클라제를 포함하는 것이 특징인 면역원성 조성물.
- 대상 분자를 CD11b 발현 세포에 특이적으로 표적화하기 위해 제형화된 인간 또는 동물에게 투여하기 위한 약학 조성물로서, 상기 대상 분자가 보르데텔라 종의 아데닐시클라제에 커플링되는 것이 특징인 약학 조성물.
- 제22항 또는 제23항에 있어서, 아데닐시클라제는 유전자 변형된 아데닐시클라제인 것인 면역원성 조성물 또는 약학 조성물.
- 제24항에 있어서, 유전자 변형된 아데닐시클라제는 대상 분자를 CD11b 발현 세포의 시토졸 내에서 특이적으로 전위시킬 수 있는 것인 면역원성 조성물 또는 약학 조성물.
- 제25항에 있어서, 상기 유전자 변형된 아데닐시클라제는 촉매 N-말단 도메인의 전부 또는 일부가 결여된 보르데텔라 아데닐시클라제인 것인 면역원성 조성물 또는 약학 조성물.
- 제25항에 있어서, 상기 유전자 변형된 아데닐시클라제는 잔기 1-373이 결여된 보르데텔라 퍼투시스 아데닐시클라제인 것인 면역원성 조성물 또는 약학 조성물.
- 제24항 또는 제25항에 있어서, 상기 유전자 변형된 아데닐시클라제는 허용 부위에서 촉매 도메인 내에 삽입된 1 이상의 시스테인 잔기(들)를 포함하는 것인 면역원성 조성물 또는 약학 조성물.
- 제22항 내지 제28항 중 어느 하나의 항에 있어서, 상기 CD11b 발현 세포는 수지상 세포, 더욱 바람직하게는 골수 수지상 세포인 것인 면역원성 조성물 또는 약학 조성물.
- 제22항 내지 제28항 중 어느 하나의 항에 있어서, 상기 CD11b 발현 세포는 호중구인 것인 면역원성 조성물 또는 약학 조성물.
- 제22항 내지 제30항 중 어느 하나의 항에 있어서, 대상 분자는 펩티드, 글리코펩티드, 리포펩티드, 다당류, 올리고당류, 핵산, 지질 및 화학약품으로 구성된 군에서 선택되는 것인 면역원성 조성물 또는 약학 조성물.
- 제22항 내지 제29항 중 어느 하나의 항에 있어서, 상기 조성물은 대상 분자에 커플링된 보르데텔라 종의 아데닐레이트 시클라제를 암호화하는 핵산 작제물을 포함하는 것인 면역원성 조성물 또는 약학 조성물.
- 제31항에 있어서, 대상 분자는 약물인 것인 면역원성 조성물 또는 약학 조성물.
- 제33항에 있어서, 약물은 항염증성 약물인 것인 면역원성 조성물 또는 약학 조성물.
- 제22항 내지 제31항 중 어느 하나의 항에 있어서, 대상 분자는 항원인 것인 면역원성 조성물 또는 약학 조성물.
- 제35항에 있어서, 항원은 세포내 박테리아 세포 항원, 종양 세포 항원, 바이러스 항원, 진균류 항원 또는 기생충 세포 항원으로 구성된 군에서 선택되는 것인 면역원성 조성물 또는 약학 조성물.
- 제36항에 있어서, 상기 항원은 폴리오바이러스 항원, HIV 바이러스 항원, 인플루엔자 바이러스 항원, 맥락수막염 바이러스 항원, 종양 항원으로 구성된 군에서 선택되는 것인 면역원성 조성물 또는 약학 조성물.
- 제35항 내지 제37항 중 어느 하나의 항에 있어서, 상기 항원이 N-말단 촉매 도메인이 결여된 유전자 변형 보르데텔라 아데닐시클라제의 N-말단부에 융합된 것인 면역원성 조성물 또는 약학 조성물.
- 제35항 내지 제38항 중 어느 하나의 항에 있어서, 상기 항원이 잔기 1-373이 결여된 유전자 변형 보르데텔라 퍼투시스 아데닐시클라제에 융합된 것인 면역원성 조성물 또는 약학 조성물.
- 제22항 내지 제39항 중 어느 하나의 항에 있어서, 조성물이 정맥내 투여용으로 제형화되고, 특히 항원 자극 보강제를 함유하지 않는 것인 면역원성 조성물 또는 약학 조성물.
- 제22항 내지 제40항 중 어느 하나의 항에 있어서, 상기 면역원성 조성물이 특이적으로 수지상 세포와 연관된 면역 반응을 유도하거나 자극할 수 있는 것인 면역원성 조성물 또는 약학 조성물.
- 백신 또는 면역요법 조성물을 제조하는 데 사용되는 제35항 내지 제39항 중 어느 하나의 항에 기재된 면역원성 조성물 또는 약학 조성물의 용도.
- 대상 분자를 CD11b 발현 세포에 특이적으로 전달하기 위한 단백질성 벡터로서, 상기 벡터는 대상 분자에 커플링된 재조합 보르데텔라 종의 아데닐시클라제를 포함하는 것이 특징인 단백질성 벡터.
- 제43항에 있어서, 상기 벡터는 또한 대상 분자를 CD11b 발현 세포의 시토졸 내로 특이적으로 전달할 수 있는 것인 단백질성 벡터.
- 제43항 또는 제44항에 있어서, 상기 CD11b 발현 세포는 수지상 세포, 더욱 바람직하게는 골수 수지상 세포인 것인 단백질성 벡터.
- 제43항 또는 제44항에 있어서, 상기 CD11b 발현 세포는 호중구인 것인 단백질성 벡터.
- 제43항 내지 제46항 중 어느 하나의 항에 있어서, 아데닐시클라제는 유전자 변형된 아데닐시클라제인 것인 단백질성 벡터.
- 제47항에 있어서, 상기 유전자 변형된 아데닐시클라제는 천연 시스테인 잔기를 포함하지 않지만, 허용 부위에서 촉매 도메인 내에 유전자 삽입된 시스테인 잔기(들)를 포함하는 것인 단백질성 벡터.
- 제47항 또는 제48항에 있어서, 아데닐시클라제는 비독성 아데닐시클라제인 것인 단백질성 벡터.
- 제47항 내지 제49항 중 어느 하나의 항에 있어서, 유전자 변형된 아데닐시클라제는 N-말단 촉매 도메인의 전부 또는 일부가 결여된 보르데텔라 아데닐시클라제인 것인 단백질성 벡터.
- 제43항 내지 제50항 중 어느 하나의 항에 있어서, 아데닐시클라제는 보르데텔라 퍼투시스에서 유래한 것인 단백질성 벡터.
- 제51항에 있어서, 상기 재조합 아데닐시클라제는 잔기 1-373이 결여된 보르데텔라 퍼투시스 아데닐시클라제인 것인 단백질성 벡터.
- 제43항 내지 제52항 중 어느 하나의 항에 있어서, 대상 분자는 펩티드, 글리코펩티드, 리포펩티드, 다당류, 올리고당류, 핵산, 지질 및 화학약품으로 구성된 군에서 선택되는 것인 단백질성 벡터.
- 제43항 내지 제53항 중 어느 하나의 항에 있어서, 대상 분자는 아데닐시클라제에 화학적으로 또는 유전자적으로 커플링된 약물인 것인 단백질성 벡터.
- 제54항에 있어서, 대상 분자는 에피토프인 것인 단백질성 벡터.
- 제54항 또는 제55항에 있어서, 상기 대상 분자는 천연 시스테인 잔기를 포함하지 않지만, 허용 부위(들)에서 촉매 도메인 내에 유전자 삽입된 시스테인 잔기(들)를 포함하는 유전자 변형된 아데닐시클라제에 화학적으로 커플링된 에피토프인 것인 단백질성 벡터.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00402562A EP1188446B1 (en) | 2000-09-15 | 2000-09-15 | Proteinaceous vectors for molecule delivery to CD11b expressing cells |
EP00402562.3 | 2000-09-15 | ||
PCT/EP2001/011315 WO2002022169A2 (en) | 2000-09-15 | 2001-09-14 | VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087015164A Division KR100953364B1 (ko) | 2000-09-15 | 2001-09-14 | CD11b 발현 세포로의 분자 전달용 벡터 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030055265A true KR20030055265A (ko) | 2003-07-02 |
KR100879151B1 KR100879151B1 (ko) | 2009-01-19 |
Family
ID=8173866
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037003818A KR100879151B1 (ko) | 2000-09-15 | 2001-09-14 | CD11b 발현 세포로의 분자 전달용 벡터 |
KR1020087015164A KR100953364B1 (ko) | 2000-09-15 | 2001-09-14 | CD11b 발현 세포로의 분자 전달용 벡터 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087015164A KR100953364B1 (ko) | 2000-09-15 | 2001-09-14 | CD11b 발현 세포로의 분자 전달용 벡터 |
Country Status (17)
Country | Link |
---|---|
US (4) | US20040001867A1 (ko) |
EP (2) | EP1188446B1 (ko) |
JP (1) | JP2004508065A (ko) |
KR (2) | KR100879151B1 (ko) |
AT (2) | ATE438409T1 (ko) |
AU (2) | AU9385501A (ko) |
BR (1) | BR0113915A (ko) |
CA (1) | CA2422603A1 (ko) |
CZ (1) | CZ2003726A3 (ko) |
DE (1) | DE60042687D1 (ko) |
ES (1) | ES2331348T3 (ko) |
HK (1) | HK1057989A1 (ko) |
HU (1) | HUP0303126A3 (ko) |
PL (1) | PL208864B1 (ko) |
PT (1) | PT1188446E (ko) |
RU (1) | RU2312143C2 (ko) |
WO (1) | WO2002022169A2 (ko) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2646776B1 (fr) | 1989-05-12 | 1994-06-03 | Pasteur Institut | Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella |
ES2331348T3 (es) | 2000-09-15 | 2009-12-30 | Pasteur Institut | Vectores proteinicos para el suministro de moleculas a las celulas que expresan cd11b. |
EP1489092A1 (en) | 2003-06-18 | 2004-12-22 | Institut Pasteur | Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof |
CA2542612A1 (en) * | 2003-10-14 | 2005-04-21 | Kingston Henry Gordon Mills | Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease |
ES2337694T3 (es) * | 2003-11-21 | 2010-04-28 | Institut Pasteur | Toxina de adenilato ciclasa recombinante de bordetella que induce las respuestas de la celula t contra los antigenos tumorales. |
DK1576967T3 (da) * | 2004-03-18 | 2008-01-21 | Pasteur Institut | Rekombinant protein, der bærer epitoper fra det humane papillomvirus indsat i et adenylatcyclaseprotein eller et fragment deraf samt dets terapeutiske anvendelse |
ES2291071B1 (es) | 2005-06-13 | 2009-03-16 | Proyecto De Biomedicina Cima, S.L. | Agentes y metodos basados en el uso del dominio eda de la fibronectina. |
ES2331271B1 (es) * | 2007-06-29 | 2010-10-14 | Universidad Del Pais Vasco | Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas. |
SG193832A1 (en) * | 2008-05-29 | 2013-10-30 | Transgene Sa | Biomarker for selecting patients and related methods |
DK2233569T3 (da) | 2009-03-23 | 2014-10-06 | Inst Of Microbiology Of The Ascr V V L | Mutante CyaA-polypeptider og polypeptidderivater egnet til at levere immunogene molekyler i en celle |
RU2585216C2 (ru) * | 2009-03-23 | 2016-05-27 | Институт Пастор | Мутантные полипептиды суаа и производные полипептидов, подходящие для доставки иммуногенных молекул в клетку |
GB201003920D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
EP2478915A1 (en) | 2011-01-24 | 2012-07-25 | Genticel | CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses |
EP2690172A1 (en) * | 2012-07-23 | 2014-01-29 | Genticel | CYAA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses |
EP2689786A1 (en) | 2012-07-23 | 2014-01-29 | Genticel | HPV/CYAA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders |
EP2975120A1 (en) | 2014-07-17 | 2016-01-20 | Institut Pasteur | Monomeric and functional adenylate cyclase CyaA toxin |
EP3323426A1 (en) | 2016-11-17 | 2018-05-23 | Ecole Nationale Vétérinaire de Toulouse | Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection |
WO2018091613A1 (en) | 2016-11-17 | 2018-05-24 | Ecole Nationale Vétérinaire de Toulouse | Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection |
EP3342421A1 (en) | 2016-12-27 | 2018-07-04 | Genticel | Immunogenic composition comprising cyaa-derived polypeptide promoting a th1/th17-oriented immune response |
JP7407721B2 (ja) * | 2017-11-03 | 2024-01-04 | アセンド バイオテクノロジー インク | 腫瘍関連骨髄系細胞の調節および免疫チェックポイント遮断の増強のための方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2601679B1 (fr) * | 1986-07-15 | 1990-05-25 | Sanofi Sa | Immunotoxines, procede de preparation et compositions pharmaceutiques en contenant |
US5182211A (en) | 1987-08-07 | 1993-01-26 | Institut Pasteur | Plasmid vectors encoding a protein of a picornavirus |
US5312902A (en) | 1988-06-09 | 1994-05-17 | Institut Pasteur | Dimer of the precursor of HIV-2 envelope glycoprotein |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
FR2638169B1 (fr) | 1988-10-25 | 1991-01-11 | Pasteur Institut | Derives d'adenyl cyclase et leurs utilisations biologiques |
EP0406857B1 (en) | 1989-07-07 | 1995-05-24 | Takeda Chemical Industries, Ltd. | Proteins and production thereof |
NO175188C (no) | 1990-06-27 | 1994-09-14 | Sjur Olsnes | Fremgangsmåte for fremstilling av et peptidkonjugat med evne til å trenge inn i cellecytosol |
US5935580A (en) * | 1992-04-21 | 1999-08-10 | Institut Pasteur | Recombinant mutants for inducing specific immune responses |
DK0637335T3 (da) * | 1992-04-21 | 2007-11-26 | Pasteur Institut | Rekombinante mutanter til induktion af specifikke immunreaktioner |
DE69612093T2 (de) * | 1995-06-07 | 2001-10-31 | Joel K Swadesh | Auf antigen verarbeitende zellen zielgerichtete konjugate ein polyaminosäure rückgrat und ein nicht-steroidales antiphlogistikum enthaltend |
US5821122A (en) | 1995-06-07 | 1998-10-13 | Inserm (Institute Nat'l De La Sante Et De La Recherche . .) | Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof |
AU2322097A (en) | 1996-03-27 | 1997-10-17 | Ortho Pharmaceutical Corporation | Lyophilized pulmonary surfactant peptide compositions |
US6333154B1 (en) * | 1997-12-04 | 2001-12-25 | Institut Pasteur | Bacterial multi-hybrid system and applications thereof |
US6673914B1 (en) | 1998-01-22 | 2004-01-06 | John Wayne Cancer Institute | Human tumor-associated gene |
CA2374237A1 (en) * | 1999-05-06 | 2000-11-16 | Wake Forest University | Compositions and methods for identifying antigens which elicit an immune response |
CN1402782A (zh) | 1999-10-19 | 2003-03-12 | 路德维哥癌症研究院 | Mage-a12抗原肽及其应用 |
ES2331348T3 (es) | 2000-09-15 | 2009-12-30 | Pasteur Institut | Vectores proteinicos para el suministro de moleculas a las celulas que expresan cd11b. |
EP1489092A1 (en) * | 2003-06-18 | 2004-12-22 | Institut Pasteur | Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof |
CA2542612A1 (en) | 2003-10-14 | 2005-04-21 | Kingston Henry Gordon Mills | Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease |
US20070026022A1 (en) | 2004-11-19 | 2007-02-01 | Gilles Dadaglio | Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens |
ES2337694T3 (es) | 2003-11-21 | 2010-04-28 | Institut Pasteur | Toxina de adenilato ciclasa recombinante de bordetella que induce las respuestas de la celula t contra los antigenos tumorales. |
DK1576967T3 (da) | 2004-03-18 | 2008-01-21 | Pasteur Institut | Rekombinant protein, der bærer epitoper fra det humane papillomvirus indsat i et adenylatcyclaseprotein eller et fragment deraf samt dets terapeutiske anvendelse |
EP1894941A1 (en) | 2006-09-01 | 2008-03-05 | Institut Pasteur | Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens |
US8017132B2 (en) * | 2009-03-23 | 2011-09-13 | Institut Pasteur | Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell |
-
2000
- 2000-09-15 ES ES00402562T patent/ES2331348T3/es not_active Expired - Lifetime
- 2000-09-15 DE DE60042687T patent/DE60042687D1/de not_active Expired - Lifetime
- 2000-09-15 AT AT00402562T patent/ATE438409T1/de active
- 2000-09-15 EP EP00402562A patent/EP1188446B1/en not_active Expired - Lifetime
- 2000-09-15 PT PT00402562T patent/PT1188446E/pt unknown
-
2001
- 2001-09-14 CA CA002422603A patent/CA2422603A1/en not_active Abandoned
- 2001-09-14 JP JP2002526418A patent/JP2004508065A/ja active Pending
- 2001-09-14 AU AU9385501A patent/AU9385501A/xx active Pending
- 2001-09-14 AU AU2001293855A patent/AU2001293855B2/en not_active Ceased
- 2001-09-14 CZ CZ2003726A patent/CZ2003726A3/cs unknown
- 2001-09-14 HU HU0303126A patent/HUP0303126A3/hu unknown
- 2001-09-14 PL PL365743A patent/PL208864B1/pl unknown
- 2001-09-14 KR KR1020037003818A patent/KR100879151B1/ko active IP Right Grant
- 2001-09-14 AT AT01974315T patent/ATE518880T1/de not_active IP Right Cessation
- 2001-09-14 WO PCT/EP2001/011315 patent/WO2002022169A2/en active IP Right Grant
- 2001-09-14 BR BR0113915-0A patent/BR0113915A/pt not_active IP Right Cessation
- 2001-09-14 EP EP01974315A patent/EP1317282B1/en not_active Expired - Lifetime
- 2001-09-14 RU RU2003110574/13A patent/RU2312143C2/ru not_active IP Right Cessation
- 2001-09-14 KR KR1020087015164A patent/KR100953364B1/ko not_active IP Right Cessation
-
2003
- 2003-03-14 US US10/387,486 patent/US20040001867A1/en not_active Abandoned
- 2003-12-04 HK HK03108857.2A patent/HK1057989A1/xx not_active IP Right Cessation
-
2005
- 2005-04-05 US US11/098,404 patent/US20050238637A1/en not_active Abandoned
-
2011
- 2011-06-27 US US13/169,605 patent/US9370564B2/en not_active Expired - Lifetime
-
2016
- 2016-06-08 US US15/177,029 patent/US10004794B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2002022169A2 (en) | 2002-03-21 |
EP1317282A2 (en) | 2003-06-11 |
BR0113915A (pt) | 2003-07-01 |
HUP0303126A2 (hu) | 2003-12-29 |
PL365743A1 (en) | 2005-01-10 |
JP2004508065A (ja) | 2004-03-18 |
AU2001293855B2 (en) | 2007-04-26 |
KR100953364B1 (ko) | 2010-04-20 |
AU9385501A (en) | 2002-03-26 |
US20050238637A1 (en) | 2005-10-27 |
US10004794B2 (en) | 2018-06-26 |
PT1188446E (pt) | 2009-11-10 |
US20120214206A1 (en) | 2012-08-23 |
EP1188446A1 (en) | 2002-03-20 |
DE60042687D1 (de) | 2009-09-17 |
EP1188446B1 (en) | 2009-08-05 |
HK1057989A1 (en) | 2004-04-30 |
US20040001867A1 (en) | 2004-01-01 |
US20160375119A1 (en) | 2016-12-29 |
KR100879151B1 (ko) | 2009-01-19 |
HUP0303126A3 (en) | 2004-10-28 |
PL208864B1 (pl) | 2011-06-30 |
ATE438409T1 (de) | 2009-08-15 |
US9370564B2 (en) | 2016-06-21 |
EP1317282B1 (en) | 2011-08-03 |
RU2312143C2 (ru) | 2007-12-10 |
ES2331348T3 (es) | 2009-12-30 |
ATE518880T1 (de) | 2011-08-15 |
CZ2003726A3 (cs) | 2003-09-17 |
WO2002022169A3 (en) | 2002-11-21 |
CA2422603A1 (en) | 2002-03-21 |
KR20080059684A (ko) | 2008-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10004794B2 (en) | Vectors for molecule delivery to CD11b expressing cells | |
US6340461B1 (en) | Superantigen based methods and compositions for treatment of diseases | |
Rock et al. | Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. | |
AU2001293855A1 (en) | Vectors for molecule delivery to CD11b expressing cells | |
Sanderson et al. | Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant | |
EP2167528A2 (en) | Modified toxins | |
JP4824550B2 (ja) | CD11b/CD18相互作用ドメインを含むかまたは欠く修飾ボルデテラアデニレートシクラーゼならびにその使用 | |
EP2268297A1 (en) | Modified toxins | |
TW201628646A (zh) | 免疫/治療性醣共軛物組合物及其用途 | |
CA2598060A1 (en) | Methods and compositions for the treatment and prevention of cancer | |
WO1997022364A1 (en) | FCε-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES, A METHOD FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
Nataraj et al. | H2-M3wt-restricted, Listeria monocytogenes-specific CD8 T cells recognize a novel, hydrophobic, protease-resistant, periodate-sensitive antigen | |
WO1993017038A1 (en) | Methods of treating diabetes | |
JP4976853B2 (ja) | ボルデテラ(Bordetella)の組換えアデニル酸シクラーゼ毒素は腫瘍抗原に対するT細胞応答を誘発する | |
Cohen et al. | Pneumococcal capsular polysaccharide is immunogenic when present on the surface of macrophages and dendritic cells: TLR4 signaling induced by a conjugate vaccine or by lipopolysaccharide is conducive | |
AU716806B2 (en) | Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins | |
AU2007203473B2 (en) | Vectors for Molecule Delivery to CD11b Expressing Cells | |
US20230211004A1 (en) | Tetanus toxoid and crm-based peptides and methods of use | |
AU2562300A (en) | Adjuvant and cell maturation agent | |
KR20220038742A (ko) | 항원성 폴리펩티드 및 이의 사용 방법 | |
Colombatti | Ricin A: structure, function and its clinical applications | |
JP2003528025A (ja) | 免疫反応調節物質アルファ2マクログロブリン複合体 | |
MXPA00009626A (en) | Immune response modulator alpha-2 macroglobulin complex |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
A107 | Divisional application of patent | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121227 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140103 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20141226 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20151228 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20161226 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20181226 Year of fee payment: 11 |